Feasibility of a Decentralized Double-Blind Randomized Controlled Trial of Zinc and Nicotinamide Riboside for the Treatment of Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are:
Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF.
Participants will:
Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

Start Date01 Jan 2025

Sponsor / Collaborator

Cedars-Sinai Health System

NCT04614714

/ Not yet recruitingPhase 2/3IIT

Nicotinamide Riboside and Milk Production in the NICU

Breastfeeding has well-established immunity and developmental benefits for newborns, yet mothers of preterm infants often struggle to provide sufficient breast milk. The investigators hypothesize that supplementing mothers of preterm infants with nicotinamide riboside (NR) during early postpartum will result in increased milk production. NR is a unique precursor to NAD+, which functions in whole-body metabolism, including that which supports the elevated energy demands of lactation. In lactating rats, NR supplementation improved milk quantity and quality, with metabolic benefits for the mother and lasting protective advantages for the offspring. No studies have been conducted to date that explore the short- or long-term use of NR for increasing milk supply in lactating women. This study will follow a small cohort of women and very preterm infants in the NICU throughout two intervention phases-- one in which each mother will randomly receive either NR or a placebo, then the opposite treatment-- to determine the effect of maternal NR supplementation on expressed milk volume and other markers of metabolism.

Start Date01 Dec 2024

Sponsor / Collaborator

University of California, Davis

NCT06324877

/ Not yet recruitingNot ApplicableIIT

Single Arm Open-label Clinical Trial in Ataxia-telangiectasia to Test the Effects of Nicotinamide Riboside on Ataxia Scales, Immune Function, and Neurofilament Light Chain.

Study design: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain. Study population: 6-10 patients with Ataxia-Telangiectasia. Dose: Nicotinamide riboside 25 mg/kg/day in 3 equal divided doses.
Primary endpoint: Scales for assessment and rating of ataxia (SARA), and International Cooperative Ataxia Rating Scale (ICARS). Improvement of at least ½ standard deviation in key clinical scales which includes either; a) significant improvement in total combined scores from the SARA and ICARS scales, and /or b) significant improvements any aspects of the SARA and ICARS scales individually, especially pertaining to; Postural and gait improvements, Improved syllable speed and articulation, Improved fine motor skills.
Secondary endpoints: Serum analysis of neurofilament light chain (Nfl), Type 1 Interferon (INFs) epigenetic signature

Start Date01 May 2024

Sponsor / Collaborator

The University of Queensland

100 Clinical Results associated with Nicotinamide riboside

100 Translational Medicine associated with Nicotinamide riboside

100 Patents (Medical) associated with Nicotinamide riboside

899

Literatures (Medical) associated with Nicotinamide riboside

01 Mar 2025·The Journal of Nutritional Biochemistry

Enhancing wound healing via modulation of autophagy-induced apoptosis: the role of nicotinamide riboside and resveratrol in streptozotocin-treated diabetic rat

Article

Author: Mazhari, Seyed Amirhossein ; Siri, Morvarid ; Esmaeili, Nafiseh ; Aryanian, Zeinab ; Saviri, Fatemeh Ghaderi ; Maleki, Mohammad Hasan ; Meybodi, Seyed Mohammadmahdi ; Dastghaib, Sanaz ; Dehghanian, Amirreza ; Naseh, Maryam

Impaired wound healing from diabetes mellitus (DM) causes lower limb amputations, posing clinical, social, and economic issues. Hypoxia and advanced glycation end products cause autophagy and apoptosis dysregulation, which delays wound healing. The study will test systemic and topical Nicotinamide Riboside (NR) and Resveratrol (RSV) for the capacity to modulate autophagy and apoptosis via the SIRT-1-FOXO1 pathway and improve diabetic wound healing. About 54 male Sprague-Dawley rats were separated into control, diabetic (T1D), T1D-Gel-Base, T1D-NR, T1D-RSV, and T1D-NR+RSV groups. Rats were gavaged with 50 mg/kg/day RSV and 300 mg/kg/day NR for 5 weeks before having their wounds topically treated with 5% NR and RSV gel for 15 days after diabetes induction. Biochemical, histomorphometric, and stereological assays were conducted. The mRNA expressions of SIRT-1, FOXO1, VEGF, BAX, Cas3, Bcl-2, Beclin1, LC3IIβ, P62, and ATG5 were examined by qRT-PCR. NR and RSV improved diabetic rat wound closure. Diabetic rats treated with NR and RSV had significantly higher LC3IIβ, VEGEF, Bcl-2, and SIRT-1 mRNA levels. Bcl-2, p62, and ATG5 were regulated whereas BAX and Cas 3 were reduced. Stereological investigations showed epidermal, dermal, collagen bundle, vascular, and fibroblast density enhancements. This study highlights the potential of NR and RSV, acting as SIRT-1 activators, in improving diabetic wound healing by regulating SIRT-1-FOXO1-mediated autophagy and apoptosis. These findings offer valuable insights for developing targeted strategies to enhance diabetic wound healing. The combination of NR and RSV showed promising effects, suggesting a potential therapeutic approach for improving diabetic wound healing.

01 Jan 2025·Biosensors and Bioelectronics

Quantitative dynamics of intracellular NMN by genetically encoded biosensor

Article

Author: Wang, Pei ; Yu, Qiuliyang ; Huang, Guan ; Chen, Liuqing ; Liu, Kaijing ; Cheng, Wenxiang

Nicotinamide mononucleotide (NMN) is the direct precursor and a major booster of NAD⁺ with increasing applications in NAD⁺- and aging-related pathologies. However, measuring live cell NMN dynamics was not possible, leaving key questions in NMN uptake and intracellular regulation unanswered. Here we developed genetically encoded bioluminescent and fluorescent sensors to quantify subcellular NMN in live cells by engineering specific NMN-responsive protein scaffolds fused to luciferase and fluorescent proteins. The sensor dissected the multimechanistic uptake of exogenous NMN and nicotinamide riboside (NR) in live cells and further measured the NMN levels across different subcellular compartments, as well as the perturbed NMN/NAD⁺ ratios by external supplements. Moreover, we measured the NMN regulation by NAD(H) hydrolase Nudts and peroxisomal carrier Pxmp2 and identified Slc25a45 as a potential mitochondrial NMN regulator for its unique fingerprint on the local NMN/NAD⁺ ratio. Collectively, the genetically encoded sensors provide a useful tool for visualizing NMN metabolism.

01 Jan 2025·Pediatric Blood & Cancer

Feasibility of telehealth exercise and nicotinamide riboside supplementation in survivors of childhood cancer at risk for diabetes: A pilot randomized controlled trial

Article

Author: Lukas, Kara ; Iukuridze, Aleksi ; Echevarria, Meagan ; Chen, Sitong ; Bhandari, Rusha ; Almeida, Brady ; Albanese, Sophia ; Wong, F. Lennie ; Guzman, Tati ; Brenner, Charles ; Rhee, June‐Wha ; Nenninger, Christian ; Shamunee, Justin ; Armenian, Saro H. ; Lindenfeld, Lanie ; Lee, Kyuwan

AbstractBackgroundChildhood cancer survivors (CCS) have a 50% higher risk of diabetes mellitus (DM) compared with the general population. Interventions in survivors with prediabetes (fasting glucose 100‐125 mg/dL or hemoglobin A1c 5.7%‐6.4%) may mitigate the development of DM and its attendant morbidity, but there is limited information on the feasibility of secondary prevention in this setting.MethodsThis 6‐week pilot feasibility 1:1 randomized controlled trial enrolled 20 CCS on a structured telehealth exercise program ± nicotinamide riboside (NR), a nicotinamide adenine dinucleotide precursor. Feasibility metrics were: (1) ≥50% of eligible CCS enrolled onto study; (2) ≥70% of participants completed baseline and end‐of‐study assessments; (3) ≥70% compliance with exercise and NR. Secondary endpoints included changes in biomarkers associated with glucose homeostasis and muscle health.ResultsMedian age (years) at cancer diagnosis was 16.5 (range, 1.5‐21.5) and 35.5 (range, 18.0‐67.0) at study enrollment. Enrollment rate was 87%, and 85% of participants completed baseline and end‐of‐study assessments. The mean percentage of exercise sessions completed was 86.6%; NR compliance was > 90%. There were no severe adverse events attributable to study interventions. Secondary endpoints were not significantly different between study arms at study completion. Myostatin decrease was observed in participants who completed a higher median number of exercise sessions and was associated with decreased intramuscular adipose tissue and increased lower extremity muscle cross‐sectional area.ConclusionsA telehealth exercise intervention ± NR supplementation was feasible in CCS with prediabetes. Future studies in larger cohorts may be needed to evaluate their beneficial effects on muscle health and DM risk among CCS.

News (Medical) associated with Nicotinamide riboside

22 Nov 2024

·www.drugs.com

Could a Vitamin Be Effective Treatment for COPD?

FRIDAY, Nov. 22, 2024 -- A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD , Danish researchers report. "This is significant, because inflammation can lead to reduced lung function in these patients," said researcher Morten Scheibye-Knudsen , of the University of Copenhagen. Patients with COPD -- the full name of which is chronic obstructive pulmonary disease -- are more likely to get pneumonia, influenza and other serious respiratory infections, which can be fatal. The new study included 40 participants with COPD and a control group of 20 healthy volunteers. They received either 2 grams a day of nicotinamide riboside -- a member of the vitamin B3 family -- or a placebo. After six weeks, researchers saw a 53% drop in a marker of inflammation known as interleukin 8, or IL 8. After 12 more weeks of vitamin therapy, the effect increased by 63%. "In other words," the researchers said in a university news release, "The group treated with vitamin B3 experienced reduced lung inflammation during the study." More study will be needed to confirm the findings and determine the long-term effect of nicotinamid riboside in treating COPD, Scheibye-Knudsen said. During the study, the team also observed that COPD patients have lower blood levels of a chemical called NAD, which appears to play a role in the aging process. NAD levels rose with vitamin B3 treatment and signs of cellular aging slowed, researchers reported Nov. 15 in the journal Nature Aging . "As we age, we seem to metabolize a molecule known as NAD," Scheibye-Knudsen said. "The loss of this molecule is also seen after DNA damage, for instance the type of damage associated with smoking." As such, he said NAD may be a target for future research and treatment. Meanwhile, his team plans a larger study to confirm the initial findings. "We hope this research will pave the way for new treatment options for COPD patients," Scheibye-Knudsen said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

26 Sep 2024

·www.businesswire.com

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

LOS ANGELES--( BUSINESS WIRE )--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors. Company Webcast The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at https://app.webinar.net/7yrd0odReoK or on the Company's website at chromadex.com. The webcast will also be available for replay following the event. 1x1 Meetings Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg . Further information on the conference is available at https://lythampartners.com/fall2024 . For additional information on ChromaDex, visit www.chromadex.com . About ChromaDex: ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen ® , the number one healthy-aging NAD+ supplement in the United States † . Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com , to which ChromaDex regularly publishes copies of its press releases, news, and financial information. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Oligonucleotide

01 Jul 2024

·www.biospace.com

ChromaDex to Join Russell 2000® Index

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024. Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented, "Joining the Russell 2000 Index reflects our sustained growth and leadership in NAD+ research. Tru Niagen® is the gold standard NAD+ supplement, backed by scientific rigor, the highest quality standards, and a robust intellectual property portfolio. This achievement underscores our commitment to driving long-term value for our shareholders as we expand our global footprint, innovate with new products, and advance the science of healthy aging." The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of Friday, June 28, 2024, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which lasts for one year, guarantees automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with the appropriate growth and value style indexes. FTSE Russell primarily determines index membership based on objective market-capitalization rankings and style attributes. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors, which contributes to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor and quality in the dietary supplement space, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside, or NR). Clinically proven to increase NAD+ levels, Niagen is the most efficient and superior-quality NAD+ booster helping people transform the way they age. Food-grade Niagen is available in the consumer dietary supplement Tru Niagen®, the number one healthy-aging oral NAD+ supplement in the United States*, and through partnerships with global retailers and distributors. Pharmaceutical-grade Niagen will soon be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.5 trillion in assets are benchmarked against Russell's U.S. indexes. FTSE Russell, a leading global index provider, administers these indexes. For more information on the Russell 2000® Index and the Russell indexes reconstitution, please visit the Russell Reconstitution Section on the FTSE Russell website. Learn more about ChromaDex by visiting . Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to ChromaDex’s inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. About ChromaDex: ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor and quality in the dietary supplement space, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside, or NR). Clinically proven to increase NAD+ levels, Niagen is the most efficient and superior-quality NAD+ booster helping people transform the way they age. Food-grade Niagen is manufactured by ChromaDex and is available in the consumer dietary supplement Tru Niagen®, the number one healthy-aging oral NAD+ supplement in the United States* (available at ). Pharmaceutical-grade Niagen will be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription ( ). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at , to which ChromaDex regularly publishes copies of its press releases, news, and financial information. *Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024). View source version on businesswire.com: Contacts ChromaDex Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-388-6706 ext. 689 kendall.knysch@chromadex.com ChromaDex Investor Relations Contact: Ben Shamsian Lytham Partners 646-829-9701 shamsian@lythampartners.com Source: ChromaDex Corporation View this news release online at:

100 Deals associated with Nicotinamide riboside

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nicotinamide riboside	A11HA01	DB14933

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute febrile illness	Phase 2	NO	ChromaDex, Inc.	01 Oct 2019
Critical Illness	Phase 2	NO	ChromaDex, Inc.	01 Oct 2019
Inflammation	Phase 2	NO	ChromaDex, Inc.	01 Oct 2019
Ataxia Telangiectasia	Phase 2	NO	Akershus Universitetssykehus HF	05 Jun 2019
Peripheral Arterial Disease	Phase 2	-	ChromaDex, Inc.	-
Head and Neck Neoplasms	Discovery	US	ChromaDex, Inc.	08 Nov 2019
Metastatic breast cancer	Discovery	US	ChromaDex, Inc.	08 Nov 2019
Metastatic endometrial cancer	Discovery	US	ChromaDex, Inc.	08 Nov 2019
Peripheral Nervous System Diseases	Discovery	US	ChromaDex, Inc.	08 Nov 2019
Platinum-Resistant Ovarian Carcinoma	Discovery	US	ChromaDex, Inc.	08 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03743636 (NICE, CTgov)	Phase 3	Peripheral Arterial Disease	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	itxsbyugfp(hqktsqaukx) = tnjddmxmtt dsvsvatgru (nnrbiicsoe, xevkvglbrh - argcqnlzcc) View more	-	14 Jan 2025
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	itxsbyugfp(hqktsqaukx) = hsaogchbyb dsvsvatgru (nnrbiicsoe, rqnqwhrqss - fajvfygqlf) View more
Biospace Manual	Phase 2	Peripheral Arterial Disease	90	Nicotinamide Riboside	(cbcxrxpvba) = bjjoxndqpa sxlosufvzg (xvxioqermj )	Positive	24 Jun 2024
				Nicotinamide Riboside combination with resveratrol	-
NCT04112043 (CTgov)	Phase 1	Hypertension	147	Walking Exercise+Nicotinamide Riboside (NR) (NR Plus Walking Exercise)	gputsquyuc(rcpagguowg) = gtunoggejt pvqauivzix (koantelghk, jfnmdzltif - yatbnffbvl) View more	-	06 Jun 2024
				Walking Exercise (Walking Exercise Plus Placebo)	gputsquyuc(rcpagguowg) = wlehcdrcbo pvqauivzix (koantelghk, rkqmguifsb - sjzagxfhrz) View more
NCT03912220 (CTgov)	Phase 2	Small Fiber Neuropathy	45	Nicotinamide riboside (Nicotinamide Riboside)	cynhyqgkqi(laxpaxoqvf) = yhgiqgjfcf qleldjskkz (ipspvqdjbu, ggjgjtbthj - qocjxglskm) View more	-	06 Jun 2024
				Placebo Oral Tablet (Placebo)	cynhyqgkqi(laxpaxoqvf) = wsvvakgydt qleldjskkz (ipspvqdjbu, cganiqwirn - qrrubzcsii) View more
NCT03151707 (CTgov)	Phase 4	-	11	Nicotinamide Riboside	zqtvbkyzoc(xelyziillm) = nqeystjpaz lsxzntpkmz (lugnsrycle, gqjuvewcjc - fahntpilds) View more	-	05 Mar 2024
NCT04818216 (NIRVANA, CTgov)	Phase 2	COVID-19 \| Acute Kidney Injury	28	Placebo (Placebo Group)	kihbuscbfd(tvefhkzujp) = ekvtvgupzt yenldbudnt (kgkoeojddw, gsqdbiwusm - hjtuyubgqv) View more	-	26 Dec 2023
				Nicotinamide riboside (Nicotinamide Riboside Group)	kihbuscbfd(tvefhkzujp) = jgcpqvfagi yenldbudnt (kgkoeojddw, cztxdaxvgk - cywyyxhfcx) View more
Biospace Manual	Phase 1	Parkinson Disease	20	Niagen 3000 mg	(tcixkjqwww) = High-dose NR was safe and well-tolerated with no related adverse events. nyaugcivos (wagiwppryx ) View more	Positive	30 Nov 2023
				placebo
NCT03642990 (CTgov)	Phase 2	Metastatic endometrial cancer \| Metastatic breast cancer \| Peripheral Nervous System Diseases \| Head and Neck Neoplasms \| Platinum-Resistant Ovarian Carcinoma	5	Nicotinamide Riboside	bujjrfplev(aovewgcpjs) = zdlhfgasrb ftnquvmbjt (hewdtnqrcp, cdwpowmthn - gwjpkwqsvn) View more	-	12 Apr 2023
ESC2021	Not Applicable	-	-	Nicotinamide Riboside	yxxogvjlik(pdeeaeevpk) = qvvharqmwy jhuankbhmj (fxupiwqcep )	-	27 Aug 2021
Pubmed \| PLoS One	Not Applicable	NADH/NAD+	8	Nicotinamide Riboside 250 mg	avtihwirab(xsikmkqywl) = Oral Not reached was well tolerated with no adverse events nxxzwubjww (vduhyxpzej ) View more	Positive	06 Dec 2017
				Nicotinamide Riboside 1000 mg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis